Elanco’s dog and cat worming brands include Milbemax and Interceptor. ACCC is awaiting information from the parties. Your comment will not appear until it has been moderated. We are strengthening our proven Innovation, Portfolio and Productivity (IPP) strategy, creating value for customers and the animals in their care. Both Bayer and Elanco sell a wide range of animal health products in Australia, including various parasiticides for companion and production animals. Bayer platzierte am Montag 54,5 Millionen Aktien der Elanco Animal Health Inc. zum Stückpreis von 30,25 US-Dollar. Required fields are marked *. The ACCC will not oppose Elanco’s acquisition of Bayer AG’s animal health business, after Elanco provided a court-enforceable undertaking to divest four animal parasite treatment brands. At completion, Bayer will receive gross proceeds of approximately 1.649 billion U.S. dollars. Bayer said it … Your comment will not appear until it has been moderated. Bayer’s sheep lice products include Avenge+ Fly, Piranha and Viper. Both Bayer and Elanco sell a wide range of animal health products in Australia, including cattle tick prevention products and various parasiticides for companion and production animals. Bayer hatte mit dem abgeschlossenen Verkauf der eigenen Tiermedizinsparte an Elanco Anfang August neben knapp 5,2 Milliarden Dollar in bar auch 72,9 Millionen Aktien von Elanco erhalten - das entsprach einem Anteil von rund 15,5 Prozent an den Amerikanern. Bayer beabsichtigt weiterhin, sich zu gegebener Zeit von seinem Anteil an Elanco zu trennen. On 9 July 2020, the ACCC announced it had accepted an undertaking (the Undertaking) from Elanco Animal Health Incorporated and its subsidiary Elanco Australasia Pty Ltd pursuant to s 87B of the Competition and Consumer Act 2010 (Cth) in connection with Elanco Animal Health Incorporated’s proposal to acquire Bayer AG’s animal health business (the Proposed Acquisition). # Kontakt ### Elanco Deutschland GmbH Werner-Reimers-Straße 2-4 61352 Bad Homburg ### Kundenbetreuung: Tel. Bayer's sheep lice products include Avenge, Piranha and Viper. Save my name, email, and website in this browser for the next time I comment. Bayer platzierte am Montag 54,5 Millionen Aktien der Elanco Animal Health Inc. zum Stückpreis von 30,25 US-Dollar. As noted in our media release, the ACCC will also issue a public competition assessment shortly – it will be on our public register when published: https://www.accc.gov.au/public-registers/mergers-registers/public-informal-merger-reviews/elanco-animal-health-incorporated-bayer-aktiengesellschaft%E2%80%99s-animal-health-business, Further information is available at Elanco Animal Health Incorporated – Bayer Aktiengesellschaft’s animal health business, Your email address will not be published. … The commission sought feedback from interested parties before making its latest decision. A proposed divestment undertaking would see Elanco selling off the Drontal, Profender and Droncit worming brands, and Bayer's Avenge+Fly sheep lice brand to purchasers approved by the ACCC. LEVERKUSEN (dpa-AFX) - Bayer (BAYZF.PK, BAYRY.PK, BYR.L) said that it has placed 54.5 million shares of Elanco Animal Health at a price of $30.25 per share. pharmaceuticals, such as parasiticides and antimicrobials and analgesics. July 9 (Reuters) - ACCC: * AUSTRALIAN COMPETITION & CONSUMER COMMISSION SAYS ELANCO’S ACQUISITION OF BAYER’S ANIMAL HEALTH BUSINESS NOT OPPOSED Source text bit.ly/3iFcrit Further company coverage: “Without the divestment, Elanco would have significantly increased its market share in the supply of sheep lice treatments,” he said. Contributions that contravene our Comments Policy will not be published. “Avenge+ Fly is an established and popular brand, and will provide a strong constraint on Elanco in the hands of a future buyer. Leverkusen, December 1, 2020 – Bayer today announced the placement of 54.5 million shares of Elanco Animal Health Incorporated (“Elanco”) at a price of 30.25 U.S. dollars per share pursuant to an SEC-registered public offering of Elanco shares on Monday. ACCC received further information from the parties. Click here if you wish Bayer PLC to keep you informed of products and marketing updates by email. 0800 / 45 34 000 ### Produkte der ehemaligen Bayer Tiergesundheit, jetzt Teil von Elanco Creative Campus: Alfred-Nobel-Straße 10 40789 Monheim ### Customer Service … Closing date for submissions relating to the draft proposed divestment undertaking. AUSTRALIA’S competition regulator will not oppose Elanco’s acquisition of Bayer AG’s animal health business. https://www.accc.gov.au/public-registers/mergers-registers/public-informal-merger-reviews/elanco-animal-health-incorporated-bayer-aktiengesellschaft%E2%80%99s-animal-health-business, Elanco Animal Health Incorporated – Bayer Aktiengesellschaft’s animal health business. Bayer hatte bereits angekündigt, das Paket wieder verkaufen zu wollen. ACCC requested further information from the parties. ELANCO ANIMAL HEALTH AKTIE und aktueller Aktienkurs. ACCC announced it would not oppose the proposed acquisition, subject to a section 87B undertaking accepted by the ACCC. THE ACCC announced today it will not oppose Elanco’s acquisition of Bayer AG’s animal health business, after Elanco provided a court-enforceable undertaking to divest four animal parasite treatment brands. Den Bruttoerlös bezifferte das Unternehmen in … The ACCC had concerns about the effect of the acquisition in the markets for sheep lice treatments, and worming treatments for cats and dogs. ACCC timeline recommenced. ACCC commenced informal review under the Informal Merger Review Process Guidelines. Closing date for submissions from interested parties. Your email address will not be published. The ACCC said it had concerns about the effect of the acquisition in the markets for sheep lice treatments, and worming treatments for cats and dogs. Bayer's sheep lice lines include Avenge, Piranha and Viper, which currently compete with Elanco's Extinosad. Bayer and Elanco do not have any manufacturing or R&D facilities based in Australia. Bayer’s sheep lice products include Avenge, Piranha and Viper. FRANKFURT (Dow Jones)--Vier Monate nach dem Verkauf seiner Tiergesundheitssparte hat Bayer sich von einem Großteil der dabei übernommenen Elanco-Aktien getrennt. Bayer hat zum Vollzug der Transaktion nach Abzug üblicher Kaufpreisanpassungen 5,17 Milliarden US-Dollar (vor Steuern) in bar sowie 72,9 Millionen Stammaktien von Elanco erhalten. ACCC commenced market consultation on proposed s87B undertaking. ACCC is awaiting further information from the parties. The ACCC had concerns about the effect of the acquisition in the markets for sheep lice treatments, and worming treatments for cats and dogs. On 9 July 2020, the ACCC announced its decision not to oppose the proposed acquisition by Elanco Animal Health Incorporated (Elanco) of Bayer Aktiengesellschaft’s (Bayer) Australian animal health business (the proposed acquisition) after accepting a section 87B undertaking to divest the Avenge+ Fly, Drontal, Profender and Droncit brands (the Undertaking). The ACCC will not oppose Elanco's acquisition of Bayer AG's animal health business, after Elanco provided a court-enforceable undertaking to divest four animal parasite treatment brands.. The ACCC has preliminary competition concerns in relation to the transaction’s consolidation of sheep lice products, and of worming treatments commonly used for cats and dogs. The Australian Competition and Consumer Commission today said Elanco had provided a court-enforceable undertaking to divest four animal parasite treatment brands. Bayer’s sheep lice products include Avenge+ Fly, Piranha and Viper. specialty products, which include immunomodulators, nutritionals, including vitamins, feed supplements and feed additives, and. Both Bayer and Elanco sell a wide range of animal health products in Australia, including various parasiticides for companion and production animals. The ACCC will not oppose Elanco’s acquisition of Bayer AG’s animal health business, after Elanco provided a court-enforceable undertaking to divest four animal parasite treatment brands. Former provisional date for announcement of findings (12 March) delayed. Elanco has said it will sell Bayer’s Avenge+Fly if it can buy Bayer AG. The ACCC said it will issue a public competition assessment shortly and publish it here. Combines Elanco’s longstanding focus on the veterinarian with Bayer Animal Health’s direct-to-consumer expertise to open new opportunities to fuel growth. ACCC deputy chair Mick Keogh said Elanco’s acquisition was likely to raise competition concerns in the supply of sheep lice treatments. Former provisional date for announcement of findings (18 June) is delayed. Die Aktienkomponente entspricht 15,5 Prozent der ausstehenden Aktien des US-Unternehmens. Scale and capabilities of the combined company position Elanco for the long term as a leader in the attractive, durable animal health industry. Bayer’s sheep lice products include Avenge, Piranha and Viper. Former provisional date for announcement of findings (30 April) is delayed. Bayer hat ein großes Paket an Aktien des US-Tiermedizinspezialisten Elanco verkauft. Elanco wird damit zum zweitgrößten Anbieter in der Tiergesundheit weltweit. Unsere wissenschaftlichen Erfolge sollen helfen, das Leben der Menschen zu verbessern. The ACCC had concerns about the effect of the acquisition in the markets for sheep lice treatments, and worming treatments for cats and dogs. 0800 / 453 48 47 Fax 0800 / 723 40 83 E-Mail: kundenbetreuung@elanco.com ### Tierärztliche Fachberatung: Tel. In Australia, this includes: Refer to the attached Public Competition Assessment. Bayer and Elanco do not have any manufacturing or R&D facilities based in Australia. Elanco Animal Health Incorporated proposes to acquire Bayer Aktiengesellschaft’s animal health business, which covers development and distribution of prescription and non-prescription products for farm and companion animals. “Drontal in particular is a strong brand, and this divestment will remove any overlap between Bayer and Elanco in worming treatments.”. Die Aktienkomponente entspricht 15,5 Prozent der ausstehenden Aktien des US-Unternehmens. These products compete with Bayer’s Drontal, Profender and Droncit products. That was the course it took earlier this year when US animal pharmaceutical company Elanco acquired the Bayer animal health business. Bayer hat zum Vollzug der Transaktion nach Abzug üblicher Kaufpreisanpassungen 5,17 Milliarden US-Dollar (vor Steuern) in bar sowie 72,9 Millionen Stammaktien von Elanco erhalten. The ACCC is seeking views on a divestment undertaking offered by Elanco in relation to its proposed acquisition of Bayer Aktiengesellschaft's animal health business. Elanco Animal Health Incorporated - Bayer Aktiengesellschaft’s animal health business, Bayer Aktiengesellschaft’s animal health business, Elanco Animal Health Incorporated and Elanco Australasia Pty Ltd - s87B undertaking - public version - 9 July 2020. https://www.accc.gov.au. In Australia, this includes: pharmaceuticals, such as parasiticides and antimicrobials and analgesics, The acquisition of Bayer Animal Health is a key step in Elanco's journey to build a fit-for-purpose global animal health leader poised for the next era of growth. Both Bayer and Elanco sell a wide range of animal health products in Australia, including cattle tick prevention products and various parasiticides for companion and production animals. Bayer hatte mit dem abgeschlossenen Verkauf der eigenen Tiermedizinsparte an Elanco Anfang August neben knapp 5,2 Milliarden Dollar in bar auch 72,9 Millionen Aktien von Elanco erhalten - … Bayer ist ein Innovationsunternehmen mit einer über 150-jährigen Geschichte. Im vergangenen Jahr hat Bayer sein Tiermedizin-Geschäft für 7,56 Milliarden Dollar an das auf Tiermedizin spezialisierte Unternehmen Elanco verkauft. Nachrichten zur Aktie Elanco Animal Health Inc Registered Shs | A2N6BH | ELAN | US28414H1032 Für die 54,5 Millionen Elanco-Aktien fließen nun 1,65 Milliarden Dollar (1,38 Mrd Euro) in die Konzernkassen. Elanco Animal Health Incorporated (NYSE: ELAN) today announced it has closed the acquisition of Bayer Animal Health. The future buyer or buyers of these brands will need to be approved by the ACCC. “In relation to worming treatments for cats and dogs, the acquisition would have removed Bayer as Elanco’s closest competitor, leaving Elanco with many of the leading worming brands,” Mr Keogh said. 01.12.2020 Elanco Animal Health Incorporated proposes to acquire Bayer Aktiengesellschaft’s animal health business, which covers development and distribution of prescription and non-prescription products for farm and companion animals. COVID-19 (coronavirus) information for consumers, Unauthorised transfer of landline & internet services, Consumer rights for landline & internet services, COVID-19 (coronavirus) information for business, Industry associations & professional services, Competing fairly in professional services, Transmission services & facilities access, Retail electricity pricing inquiry 2017-2018, Monitoring & reporting for container stevedoring, Australian Competition & Consumer Commission, Compliance & enforcement policy & priorities, UniSA & ACCC Competition Law & Economics Workshop, Mergers & Competition Exemptions consultations, Digital platform services inquiry 2020-2025, Murray-Darling Basin water markets inquiry, Feminine hygiene products price monitoring, Foreign currency conversion services inquiry, Residential mortgage products price inquiry, Authorisations and notifications registers, Collective bargaining notifications register, Resale Price Maintenance notifications register. Für 7,6 Milliarden Dollar erwirbt das US-Unternehmen Elanco die Animal Health GmbH von Bayer. GREENFIELD, Ind. An ACCC spokesman said the feedback from the market indicated that Avenge is a strong brand and would effectively address the ACCC’s competition concerns. Bayer and Elanco do not have any manufacturing or R&D facilities based in Australia. July 9 (Reuters) - ACCC: * AUSTRALIAN COMPETITION & CONSUMER COMMISSION SAYS ELANCO’S ACQUISITION OF BAYER’S ANIMAL HEALTH BUSINESS NOT OPPOSED Source text bit.ly/3iFcrit Further company coverage: Bayer hatte mit dem abgeschlossenen Verkauf der eigenen Tiermedizinsparte an Elanco Anfang August neben knapp 5,2 Milliarden Dollar in bar auch 72,9 Millionen Aktien von Elanco erhalten - … Elanco will divest the sheep lice treatment Avenge+ Fly, as well as the cat and dog intestinal worm treatments Drontal, Profender and Droncit. (August 3, 2020) – Elanco Animal Health Incorporated (NYSE: ELAN) today announced it has closed the acquisition of Bayer Animal Health. The transaction, valued at $6.89 billion, expands Elanco’s scale and capabilities, positioning the company for the long term as a leader in the attractive, durable animal health industry. These products compete with Elanco’s Extinosad sheep lice product. Bayer and Elanco do not have any manufacturing or R&D facilities based in Australia. Dadrch strich der Agrarchemie- und Pharmakonzern einen Milliardenbetrag ein.